Prostatype Genomics
Prostatype Genomics AB: Rights issue registered and trading in paid subscription units ceases
REG
For further information about Prostatype Genomics, please contact:
Fredrik Persson, CEO
Telephone: +46 (0) 73 049 77 01.
e-mail: fredrik.persson@prostatypegenomics.com
Certified Adviser
Carnegie Investment Bank AB (publ), +46 (0)73 856 4265, certifiedadviser@carnegie.se
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
Datum | 2024-01-16, kl 09:30 |
Källa | Cision |
![](https://static.allaaktier.se/ads/etoro-logo.png)
Copy Trading innebär inte investeringsråd. Värdet på dina investeringar kan gå upp eller ned. Ditt kapital löper risk.